Scarica l'app Stockscreener
3.96
3.18%
-0.13
Dopo l'orario di chiusura:
3.97
0.01
+0.25%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$4.09
Aprire:
$4.082
Volume 24 ore:
5.62M
Relative Volume:
1.42
Capitalizzazione di mercato:
$413.20M
Reddito:
$409.00K
Utile/perdita netta:
$-101.35M
Rapporto P/E:
-2.4146
EPS:
-1.64
Flusso di cassa netto:
$-71.49M
1 W Prestazione:
+9.70%
1M Prestazione:
-24.43%
6M Prestazione:
-16.81%
1 anno Prestazione:
-45.38%
Intervallo 1D:
$3.8601
$4.18
Intervallo di 1 settimana:
$3.48
$4.53
Portata 52W:
$2.90
$7.83
Altimmune Inc Stock (ALT) Company Profile
Nome
Altimmune Inc
Settore
Industria
Telefono
(240) 654-1450
Indirizzo
910 CLOPPER ROAD, GAITHERSBURG, MD
Confronta ALT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
3.96 | 426.76M | 409.00K | -101.35M | -71.49M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-10 | Ripresa | Goldman | Sell |
| 2025-02-28 | Iniziato | William Blair | Mkt Perform |
| 2025-01-08 | Iniziato | Stifel | Buy |
| 2024-11-12 | Iniziato | UBS | Buy |
| 2024-04-29 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-01-24 | Iniziato | Goldman | Neutral |
| 2023-03-22 | Downgrade | Goldman | Buy → Neutral |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2021-12-29 | Ripresa | Jefferies | Buy |
| 2021-06-02 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-11 | Iniziato | Guggenheim | Buy |
| 2020-12-14 | Iniziato | Jefferies | Buy |
| 2020-11-12 | Reiterato | B. Riley Securities | Buy |
| 2020-09-25 | Iniziato | B. Riley FBR | Buy |
| 2020-08-14 | Iniziato | Evercore ISI | Outperform |
| 2020-07-31 | Iniziato | Piper Sandler | Overweight |
| 2020-07-28 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-02-24 | Ripresa | ROTH Capital | Buy |
| 2019-07-19 | Iniziato | ROTH Capital | Buy |
| 2017-10-09 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Altimmune Inc Borsa (ALT) Ultime notizie
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
ALT Stock Up 17% After Pemvidutide Gets FDA Breakthrough Tag for MASH - sharewise.com
Altimmune’s Surprising Stock Surge: What’s Behind It? - StocksToTrade
Altimmune, GH Research, Gyre Therapeutics And Other Big Stocks Moving Higher On Monday - Benzinga
Altimmune shares rally after FDA awards breakthrough status to pemvidutide - MSN
Why Did Mobileye Stock Surge 8% Pre-Market Today? - Stocktwits
Altimmune (ALT) Surges on FDA Breakthrough Therapy Designation f - GuruFocus
Altimmune stock gains on FDA breakthrough status (ALT:NASDAQ) - Seeking Alpha
FDA grants breakthrough therapy status to Altimmune’s MASH drug By Investing.com - Investing.com Australia
Altimmune jumps after US FDA's 'breakthrough' tag for liver disease drug - TradingView — Track All Markets
Altimmune, Inc. Receives FDA Breakthrough Therapy Designation for Pemvidutide in Treating Metabolic Dysfunction-Associated Steatohepatitis (MASH) - Quiver Quantitative
Altimmune stock soars after FDA grants Breakthrough Therapy status By Investing.com - Investing.com Canada
Altimmune stock soars after FDA grants Breakthrough Therapy status - Investing.com
FDA flags new liver disease drug for faster review after promising early data - Stock Titan
Altimmune Receives FDA’s Breakthrough Therapy Designation For Its Liver Disease Drug - Stocktwits
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround - The Globe and Mail
Jerome Durso Buys Handful Of Shares In Altimmune - Yahoo Finance
Insider Buying: Altimmune Independent Chairman Bought US$52k Of Shares - simplywall.st
Altimmune, Pure Storage, Globalstar, Cipher Mining, AutoZone Shake-Up - TipRanks
Altimmune announces CEO transition - MSN
Q3 2025 Altimmune Inc Earnings Call Transcript - GuruFocus
Does Altimmune (ALT) have the potential to rally 229.28% as Wall Street analysts expect? - MSN
Insider Buying: John Gill Acquires 12,500 Shares of Altimmune In - GuruFocus
Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha
John Gill Acquires 12,500 Shares of Altimmune (NASDAQ:ALT) Stock - MarketBeat
Altimmune Director John Gill Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune stock soars over 10% premarket on positive mid-stage data for liver disease treatment drug - MSN
Altimmune, Inc. (NASDAQ:ALT) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Insider Buying: Jerome Durso Acquires 12,500 Shares of Altimmune Inc (ALT) - GuruFocus
Altimmune (NASDAQ:ALT) Director Jerome Benedict Durso Purchases 12,500 Shares - MarketBeat
Altimmune’s 48-Week MASH Data Still Leave Doubts On Fibrosis Benefit - Citeline News & Insights
Altimmune Director Jerome Benedict Durso Acquires 12,500 Shares - TradingView — Track All Markets
Altimmune: Positives And Negatives Of The IMPACT Data And Recent Updates - Seeking Alpha
Altimmune Slides As Insider Purchases Lose Another US$15k - 富途牛牛
Altimmune Stock Plummets After Disappointing Trial Results - timothysykes.com
Would You Still Hold Altimmune Stock If It Fell Another 30%? - Trefis
Can Altimmune Inc. stock hit analyst price targetsJuly 2025 Reactions & Weekly Watchlist for Hot Stocks - Улправда
How Altimmune Inc. stock compares to market leadersPortfolio Risk Report & Weekly Setup with High ROI Potential - Улправда
Will Altimmune Inc. stock benefit from upcoming earnings reports2025 Price Targets & Community Consensus Trade Signals - Улправда
Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASHSlideshow (NASDAQ:ALT) 2025-12-19 - Seeking Alpha
Why Is Altimmune Stock Up Over 10% Before The Bell? - Stocktwits
Altimmune (ALT) Shares Plunge Following Phase 2b MASH Trial Resu - GuruFocus
ALT Stock Surge: Should You Act? - StocksToTrade
Altimmune's liver disease drug shows benefits in study, but investors remain unimpressed - MSN
Balanced Risk-Reward for Altimmune’s Pemvidutide in a Crowded MASH Landscape Supports Hold Rating - TipRanks
Pemvidutide’s Strong Phase 2b Data and De-Risked Phase 3 Path in MASH Support Altimmune Buy Rating and $12 Target - TipRanks
Altimmune stock tumbles after MASH drug trial data By Investing.com - Investing.com Nigeria
Altimmune stock tumbles after MASH drug trial data - Investing.com
Transcript : Altimmune, Inc.Special Call - marketscreener.com
Altimmune advances in MASH; New China obesity biotech; Ipsen Phase 2 fail - Endpoints News
Altimmune Inc Azioni (ALT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.52%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):